= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Cobbaert

MSACL 2018 EU Abstract

Topic: Proteomics

Podium Presentation in the Ether on Thursday at 11:00 (Chair: Renee Ruhaak)

Paving the Way for MS-based Protein Tests that Target Unmet Clinical Needs

Christa Cobbaert (Presenter)
Leiden University Medical Center

Presenter Bio(s): Christa Cobbaert is head and professor of the Department of Clinical Chemistry and Laboratory Medicine at the Leiden University Medical Center. Her scientific research focuses on test evaluation with great attention to standardization, harmonization and trueness verification of medical test results, for the sake of better of patient care. Her scientific work is done in close collaboration with the Dutch External Quality Assessment Scheme organizer (SKML) and with international colleagues which collaborate in joint working groups. Her efforts resulted in ca. 150 original publications and several appointments on (inter)national positions because of her expertise on metrological traceability of test results. She is currently vice chair of the International Federation of Clinical Chemistry (IFCC) Scientific Division EC and member of ISO TC 212/ working group 2.

Authors: Christa M. Cobbaert (1), L. Renee Ruhaak (1), Arnoud van der Laarse (1), Wilma E. Mesker (2), Rob A. E. M. Tollenaar (2) Manfred Wuhrer (3), Yuri E.M. van der Burgt (1,3)
Leiden University Medical Center, Leiden, the Netherlands


Proteins in body fluids are routinely tested in clinical laboratories by immunoassays, however diagnostic sensitivity- and specificity may not be sufficient for the intended use. Moreover, the applied immunoassays cannot recognize the different proteoforms, whereas MS-based strategies result in detailed structural characterization of specific protein targets. Furthermore, clinically effective tests that support patient management at an early and curable stage are lacking for a wide variety of diseases. In our institute we define specific unmet clinical needs with the clinicians according to a structured checklist developed by the European Federation of Laboratory Medicine Working Group on Test Evaluation and explore quantitative clinical chemistry proteomics as a strategy to detect and quantitate specific proteins in a multiplexed way.

Financial Disclosure

Board MemberyesMSACL\'s scientific committee on proteomics
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: